help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology, doi:10.1210/en.2007-1458
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xie, T.
Right arrow Articles by Weinstein, L. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xie, T.
Right arrow Articles by Weinstein, L. S.
Endocrinology Vol. 149, No. 5 2443-2450
Copyright © 2008 by The Endocrine Society

Severe Obesity and Insulin Resistance due to Deletion of the Maternal Gs{alpha} Allele Is Reversed by Paternal Deletion of the Gs{alpha} Imprint Control Region

Tao Xie, Min Chen, Oksana Gavrilova, Edwin W. Lai, Jie Liu and Lee S. Weinstein

Metabolic Diseases Branch (T.X., M.C., J.L., L.S.W.) and Mouse Metabolism Core Laboratory (O.G.), National Institute of Diabetes and Digestive and Kidney Diseases, and Reproductive and Adult Endocrinology Program (E.W.L.), National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892

Address all correspondence and requests for reprints to: Lee S. Weinstein, M.D., Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health, Building 10, Room 8C101, Bethesda, Maryland 20892-1752. E-mail: leew{at}amb.niddk.nih.gov.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The G protein {alpha}-subunit Gs{alpha} mediates receptor-stimulated cAMP production and is imprinted with reduced expression from the paternal allele in specific tissues. Disruption of the Gs{alpha} maternal (but not paternal) allele leads to severe obesity, hypertriglyceridemia, and insulin resistance in mice and obesity in patients with Albright hereditary osteodystrophy. Paternal deletion of a Gs{alpha} imprint control region (1A) leads to loss of tissue-specific Gs{alpha} imprinting. To determine whether the metabolic abnormalities resulting from disruption of the Gs{alpha} maternal allele could be reversed by loss of paternal Gs{alpha} imprinting, females with a heterozygous Gs{alpha} exon 1 deletion were mated to males with heterozygous deletion of the imprint control region (1A) to generate mice with maternal Gs{alpha} deletion (E1m–), paternal 1A deletion (1Ap–), double mutants (E1m–:1Ap–), and wild type. E1m– mice developed obesity, glucose intolerance, insulin resistance, and hypertriglyceridemia, which were all normalized by the paternal 1A deletion in E1m–:1Ap– mice. Obesity in E1m– was associated with reduced energy expenditure and sympathetic nerve activity, and these were also normalized in E1m–:1Ap– mice. 1Ap– mice had reduced body weight associated with proportional decreases in fat and lean mass as well as increased activity levels. The metabolic phenotype resulting from maternal Gs{alpha} deletion is rescued by a genetic lesion that leads to loss of tissue-specific Gs{alpha} imprinting, consistent with this phenotype being a direct consequence of Gs{alpha} imprinting in one or more specific tissues.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
THE INCIDENCE OF metabolic syndrome, characterized by obesity, insulin resistance, and diabetes, has dramatically increased over the past 2 decades. Studies of monogenic obesity disorders provide important insights into genes involved in the development of the metabolic syndrome and the mechanisms by which they impact energy and glucose metabolism (1). One such disease is Albright hereditary osteodystrophy (AHO), a disorder characterized by short stature and skeletal and neurological abnormalities (2). The underlying genetic defect is heterozygous loss-of-function mutation of the ubiquitously expressed G protein {alpha}-subunit Gs{alpha}, which is required for receptor-stimulated cAMP generation. In addition to these clinical features, patients who inherit Gs{alpha} mutations from their mother also develop resistance to several hormones, such as PTH and thyroid-stimulating hormone, and obesity (referred to as pseudohypoparathyroidism type 1A). Similarly, mice with disruption of the Gs{alpha} maternal allele develop severe obesity, insulin resistance, and hypertriglyceridemia, whereas the same mutation on the paternal allele leads to only very mild obesity and insulin resistance (3).

Studies have shown that these parent-of-origin effects of Gs{alpha} mutations on hormone resistance are due to the fact that Gs{alpha} is imprinted in a tissue-specific manner, being expressed primarily from the maternal allele (suppressed on the paternal allele) in hormone-target tissues, such as the renal proximal tubules, thyroid, gonads, and pituitary somatotrophs (4, 5, 6, 7, 8). In fact, Gs{alpha} is just one product of the complex imprinted gene GNAS on human chromosome 20q13 (2, 9). In addition to Gs{alpha}, this gene has alternative upstream promoters for two other gene products, the chromogranin-like protein NESP55 and the alternative Gs{alpha} isoform XL{alpha}s, which are expressed only from the maternal and paternal alleles, respectively (Fig. 1AGo). Transcript-specific knockouts of the mouse ortholog Gnas have helped to define the roles of each gene product in development and metabolic regulation (9). Heterozygous deletion of Gs{alpha} exon 1 (E1–) on the maternal allele leads to reduced postnatal survival, severe perinatal sc edema, severe obesity, insulin resistance, and hypertriglyceridemia, whereas the same deletion on the paternal allele leads to normal survival, no sc edema, and only a mild increase in adiposity and insulin resistance (3, 10). Another model in which maternal Gs{alpha} was disrupted in exon 2 also led to obesity and reduced energy expenditure, although glucose metabolism was not similarly affected (11). XL{alpha}s deficiency leads to a lean and insulin-sensitive phenotype with a defect in neonatal suckling in mice (12, 13) whereas NESP55 has no major role in metabolic regulation in either mice or humans (14, 15). The role of XL{alpha}s in humans is less clear (9).


Figure 1
View larger version (28K):
[in this window]
[in a new window]

  		FIG. 1. Organization and imprinting of the Gnas locus and cross-mating of mice with different Gnas mutations. A, The maternal and paternal alleles of the Gnas locus are depicted showing four alternative first exons for NESP55 (NESP), XL{alpha}s, 1A mRNA transcripts, and Gs{alpha} (exon 1) splicing onto common exons 2–13 (shown as a single box). Regions of differential methylation (METH) are shown above and splicing patterns are shown below each allele. Active promoters are shown in white with horizontal arrows, whereas inactive promoters are shown in gray. The thin and dashed arrow for the paternal Gs{alpha} promoter indicates that this promoter is suppressed in a tissue-specific manner due to genomic imprinting. B, Female mice with paternal deletion of Gs{alpha} exon 1 (E1p–) were mated to males with a paternal deletion of the 1A DMR (1Ap–) to generate wild-type (+/+), E1m– (maternal deletion of Gs{alpha} exon 1), 1Ap–, and double-mutant (E1m–:1Ap–) mice. Below each genotype is a schematic showing deletions with an X and indicating the expected effect on Gs{alpha} expression. The survival rate at weaning expressed as both total number (n = 370 total offspring) and percent of wild-type as well as the presence or absence of sc edema at birth are indicated for each group of mice.

 
Tissue-specific suppression of Gs{alpha} expression from the paternal allele is not associated with methylation of the Gs{alpha} promoter (16, 17). Rather, tissue-specific Gs{alpha} imprinting is dependent on a differentially methylated region (1A DMR) located 2 kb upstream of the Gs{alpha} promoter (15, 16) (Fig. 1AGo). This region is an imprinting control region for Gs{alpha} as paternal deletion of this region leads to loss of tissue-specific Gs{alpha} imprinting (18, 19). This region contains an alternative first exon (exon 1A) that is expressed only from the paternal allele and that splices onto Gs{alpha} exon 2 to produce an mRNA that does not encode a fully functional protein (15, 16). The role, if any, of this transcript is unknown, but it is unlikely to be involved in Gs{alpha} imprinting because it is ubiquitously expressed in a similar tissue distribution as that of Gs{alpha} transcripts (16). Rather, we speculated that the region contains one or more cis-acting negative regulatory elements for the Gs{alpha} promoter that acts in a methylation-sensitive and tissue-specific manner (18).

It is presumed that differences in the phenotypes between mice with maternal vs. paternal E1– mutations result from differences in Gs{alpha} expression in tissues in which Gs{alpha} is normally imprinted, leading to much more severe Gs{alpha} deficiency in maternal E1– mice (E1m–). If this is correct, the presence of a 1A DMR deletion on the paternal allele (1Ap–) should rescue the phenotype due to loss of tissue-specific Gs{alpha} imprinting. In this study we generated E1m–, 1Ap–, and double mutant (E1m–:1Ap–) mice and show that the E1m– metabolic phenotype is completely corrected by the presence of the paternal 1A DMR deletion, providing further evidence that the metabolic phenotype is a direct consequence of Gs{alpha} imprinting in one or more specific tissues. In addition, we show the 1Ap– mutation alone has effects on growth and activity levels.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Animals
To generate mice, female E1p– and male 1Ap– mice (3, 18) with deletion of Gs{alpha} exon 1 or the 1A DMR on the paternal allele, respectively, were mated. All mice were on a CD-1 genetic background and maintained on standard pellet diet (NIH-07, 5% fat by weight) and 12-h light, 12-h dark cycle. Except when noted, all experiments were performed on 12- to 14-wk-old male mice. Experiments were approved by the National Institute of Diabetes and Digestive and Kidney Diseases Animal Care and Use Committee and conducted in accord with accepted standards of humane animal care, as outlined in the ethical guidelines.

Body composition, food intake, metabolic rate, and activity measurements
Body composition was measured using the Echo MRI3-in-1 (Echo Medical Systems, Houston, TX). Food intake, metabolic rates (oxygen consumption rate by indirect calorimetry), and activity levels were determined as previously described (11).

Histology
Dissected samples were fixed overnight in 4% paraformaldehyde, embedded in paraffin, cut, and stained with hematoxylin and eosin.

Blood and urine chemistries
Blood was obtained by retroorbital bleed. Serum glucose, cholesterol, and triglyceride levels were measured by autoanalyzer at the National Institutes of Health Clinical Chemistry Laboratory. Serum insulin, leptin, and free T4 were measured by ELISA (Millipore, Billerica, MA). TSH and IGF-I were measured by RIA (Alpco Diagnostics, Windham, NH). Urine was collected by bladder puncture and catecholamines were measured by HPLC (20) and corrected by creatinine concentration within the same samples, which were measured by Ani-Lytics, Inc. (Gaithersburg, MD).

Glucose and insulin tolerance tests
Glucose and insulin tolerance tests were performed in overnight fasted mice after ip injection of glucose (2 mg/g) or insulin (Humulin, 0.50 mIU/g), respectively. Blood glucose levels in tail vein bleeds were measured using a Glucometer Elite (Bayer, Elkhart, IN) at indicated times before and after injection.

Quantitative RT-PCR
RNA was extracted from brown adipose tissue (BAT) using TRIzol (Invitrogen, Carlsbad, CA) and treated with DNase (DNA-free; Ambion, Austin, TX) to remove DNA contamination. Reverse transcription was performed using the SuperScript first-strand synthesis system (Invitrogen). Gene expression levels were measured by quantitative RT-PCR using a real-time PCR machine (MxP3000; Stratagene, La Jolla, CA). PCRs (20 µl total volume) included cDNA, 100 nM primers, and 10 µl of SYBR Green master mix (Applied Biosystems, Foster City, CA). To get relative quantification, standard curves were simultaneously generated with serial dilutions of cDNA, and results were normalized to β-actin mRNA levels in each sample, which were determined simultaneously by the same method. Specificity of each RT-PCR product was indicated by its dissociation curve and the presence of a single band of expected size on acrylamide gel electrophoresis. Primer sequences used for each gene have been previously published (13).

Statistical analysis
Data are expressed as mean ± SEM. Statistical significance between groups was determined using one- or two-factor ANOVA with Bonferroni posttest analysis or unpaired t test with differences considered significant at P < 0.05.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Paternal 1A deletion reverses perinatal sc edema and lethality due to maternal Gs{alpha} disruption
Females heterozygous for a deletion of Gs{alpha} exon 1 on the paternal allele (E1p–) were mated with males heterozygous for a deletion of the 1A DMR on the paternal allele (1Ap–) to generate four groups of offspring: wild-type (+/+) mice, mice with disruption of Gs{alpha} expression on the maternal allele (E1m–), mice with deletion of the 1A imprinting control region on the paternal allele (1Ap–), and mice with both maternal disruption of Gs{alpha} and paternal deletion of 1A (E1m–:1Ap–) (Fig. 1BGo). E1p– as opposed to E1m– mothers were used in the study to minimize any potential maternal gestational effects because these mice have a much less severe phenotype (3). Genetic analysis of 370 total offspring that survived to weaning showed that E1m– had only 56% survival to weaning, compared with +/+ mice, similar to previously published results (3). 1Ap– mice had a very small reduction in survival (92% of +/+ mice), whereas the paternal 1A– deletion partially rescued the lethality resulting from maternal loss of Gs{alpha} expression with E1m–:1Ap– mice having an 80% survival rate compared with +/+ mice. All E1m– offspring had severe sc edema at birth despite the fact that their mothers who were E1p– never developed perinatal edema. In addition, when female E1m–:1Ap– mice, which had a normal phenotype, were mated with wild-type males, the E1m– offspring all had perinatal sc edema, confirming that this phenotype is due to loss of the maternal Gs{alpha} allele in the offspring, rather than a maternal effect. In contrast, the edema was absent in all E1m–:1Ap– pups, similar to previous reports, suggesting that the edema in E1m– mice was a consequence of Gs{alpha} imprinting (3, 18, 19).

Paternal 1A deletion reverses the obesity of E1m– mice
Both male and female E1m– mice gained significantly more weight than +/+, E1m–:1Ap–, and 1Ap– mice over the first 20 wk of life (Fig. 2AGo), similar to previously published results (3). In contrast, both male and female 1Ap– mice gained less weight than +/+ mice, although this difference was significant only in males. The presence of the paternal 1A deletion reversed the increased weight gain resulting from the E1m– mutation, with both male and female E1m–:1Ap– mice having weight curves between those of +/+ and 1Ap– mice. These weight differences were not associated with differences in body length (Fig. 2BGo). Consistent with the lack of effects on length, there were also no significant differences in serum IGF-I levels between the groups (Fig. 2CGo). In males the body mass index [BMI; weight in grams/(nasoanal length in centimeters) squared] was significantly greater in E1m– than +/+ mice, and this increase was reversed in E1m–:1Ap– mice (Fig. 2DGo). BMI was minimally reduced in 1Ap– mice, compared with +/+ mice.


Figure 2
View larger version (62K):
[in this window]
[in a new window]

  		FIG. 2. Effects of genotype on growth and body composition. A, Growth curves for male (left) and female (right) mice for each genotype (n = 2–14 animals/measurement). Two-way ANOVA with Bonferroni’s posttest analysis showed that by 14 wk both male and female E1m– mice had significantly greater growth than the other three groups, and male 1Ap– mice had significantly less growth than +/+ mice. Nasoanal body length (B), serum IGF-I levels (C), and BMI [weight in grams/(nasoanal length in cm) squared] (D) in adult male mice (n = 6–18/group). E, Fat mass expressed as percent of total body weight in male (left) and female (right) adult mice (n = 6–14/group). F, Weight (as percent body weight) of interscapular BAT (left) and parametrial (Abd; right) fat pads in adult females (n = 5–7/group). G, Histological sections of interscapular BAT obtained from adult mice and stained with hematoxylin and eosin. H, Serum leptin levels in nonfasted adult male mice (n = 7–11/group). *, P < 0.05 vs. +/+; ^, P < 0.05 vs. E1m–; #, P < 0.05 vs. E1m–:1Ap–.

 
Body composition analysis by nuclear magnetic resonance confirmed that both male and female E1m– mice have increased fat mass, as previously reported (3), and that this increase is reversed in E1m–:1Ap– mice (Fig. 2EGo). The reduced body weights observed in male 1Ap– mice (Fig. 2AGo) were due to similar reductions in both fat and lean mass (Fig. 2EGo and data not shown). Consistent with the body composition data,. female E1m– mice had increased abdominal (parametrial) white adipose tissue and interscapular BAT pad masses (as percent body weight) compared with +/+ mice, whereas the white adipose tissue and BAT fat pad masses of E1m–:1Ap– and 1Ap– mice were similar to +/+ mice (Fig. 2FGo). Histology of interscapular BAT showed E1m– mice to have larger adipocytes with increased lipid accumulation per cell compared with the other three groups (Fig. 2GGo). Finally, serum leptin levels, which reflect overall adiposity, were almost 3-fold higher in E1m– mice compared with +/+, E1m–:1Ap–, and 1Ap– mice (Fig. 2HGo). Overall these findings show that the obesity in E1m– mice is reversed by the presence of paternal 1A– deletion in E1m–:1Ap– mice and that the 1Ap– mutation has a small independent effect on body weight but a minimal effect on adiposity. Differences in adiposity were not due to differences in thyroid hormone status, as serum free T4 and TSH levels were similar in the four groups (data not shown).

Paternal 1A deletion reverses the reduced energy expenditure of E1m– mice
We next examined food intake, energy expenditure, and activity levels in our four groups of mice to determine which of these parameters are impacting the observed differences in adiposity. We found no differences in absolute food intake per day among the four groups despite the increased body weight of E1m– mice. When food intake was normalized to body weight E1m– actually ate less despite their increased adiposity, and this difference was reversed by the presence of the paternal 1A– deletion in E1m–:1Ap– mice, with no independent effect of the 1Ap– mutation alone (Fig. 3Go, A and B).


Figure 3
View larger version (53K):
[in this window]
[in a new window]

  		FIG. 3. Effects of genotype on energy balance and activity levels. A, Total food intake (grams per day) in adult male mice (n = 5–9/group). B, Food intake data normalized by body weight. C, Resting and total energy expenditure rates normalized to body weights (vO2 in milliliters per gram0.75 per hour) at 23 and 30 C in adult male mice (n = 6–8/group). D, Total and ambulatory activity levels in male mice at 23 and 30 C (n = 6–8/group). E, Urine DHPG, NE, and EPI levels normalized to creatinine concentration (n = 7–13/group). F, Relative expression of four genes involved in thermogenesis and mitochondrial function in interscapular BAT (n = 4–6/group). *, P < 0.05 vs. +/+; ^, P < 0.05 vs. E1m–.

 
Similar to previously published results (3), E1m– had reduced resting energy expenditure (O2 consumption) at both room (23 C) and thermoneutral (30 C) temperatures, compared with +/+ mice (Fig. 3CGo). This difference was reversed by the presence of the paternal 1A– allele in E1m–:1Ap– mice. In fact, resting energy expenditure at 23 C was slightly greater in 1Ap– mice compared with +/+ mice. A similar pattern was observed for total energy expenditure, except for the fact that total energy expenditure at 23 C was clearly elevated in E1m–:1Ap– and 1Ap– mice compared with +/+ mice. This increase in total energy expenditure in these two groups of mice is likely explained by the fact that they have markedly increased ambulatory and total activity levels (Fig. 3DGo). Similar to our previous study (3), we observed no differences in activity levels between E1m– and +/+ mice.

Previous studies have suggested that disruption of the maternal Gs{alpha} allele leads to reduced energy expenditure by a decrease in sympathetic nervous system activity (11). To examine this, we measured urine catecholamine levels, which were normalized to creatinine concentration to correct for differences in urine concentration and lean body mass (Fig. 3EGo). There were no differences in serum creatinine among the four groups (data not shown). Compared with +/+ mice, urine levels of norepinephrine (NE) and its metabolite dihydroxyphenylglycol (DHPG) were reduced in E1m– (P = 0.07 for NE), consistent with these mice having reduced sympathetic nervous system activity as a likely contributor to their lower-than-normal energy expenditure rates. Epinephrine (EPI), which is primarily secreted from the adrenal medulla, also tended to be lower in E1m– mice. In contrast, urine DHPG, NE, and EPI concentrations in E1m–:1Ap– and 1Ap– mice were all similar to those in +/+ mice. This correlates with the differences in energy expenditure observed between groups and demonstrates that the presence of the paternal 1A– deletion reverses both the reduced sympathetic activity and energy expenditure levels that result from disruption of Gs{alpha} on the maternal allele.

We next examined the expression of BAT genes involved in energy metabolism that are directly induced by sympathetic nerve stimulation (Fig. 3FGo). Peroxisome proliferator-activated receptor-{gamma} coactivator (PGC)-1{alpha} is a cAMP-inducible gene that activates genes required for mitochondrial function and thermogenesis (21). Due to great variability in the samples, we were unable to detect differences in BAT PGC1{alpha} expression among the groups, although PGC1{alpha} expression tended to be lower in the E1m– samples. However, expression of the thermogenic uncoupling protein (Ucp1) gene and mitochondrial transcription factor A (Tfam), a gene involved in mitochondrial function, were both reduced in BAT from E1m– mice, consistent with their reduced energy expenditure rates and sympathetic activity. Nuclear regulatory factor 1 (Nrf1), another gene involved in mitochondrial function, tended to be lower in E1m– mice compared with +/+ mice, and was significantly lower in E1m– mice than in E1m–:1Ap– mice. In contrast, expression of these three genes in BAT from E1m–:1Ap– or 1Ap– mice was similar to that in +/+ mice, consistent with the normal levels of energy expenditure and sympathetic activity observed in these two groups of mice. Overall, our results demonstrate that the 1Ap– mutation reverses the reduced energy expenditure and sympathetic nervous system activity observed in E1m– mice and has little or no independent effect on these parameters. Moreover, the presence of the paternal 1A– deletion is associated with increased activity levels.

Paternal 1A deletion reverses abnormal glucose and lipid metabolism of E1m– mice
We observed no differences in serum cholesterol levels among the four groups of mice (Fig. 4AGo). Similar to previously published results (3), serum triglyceride levels were elevated in E1m– mice, compared with +/+ mice (Fig. 4BGo). Hypertriglyceridemia resulting from the E1m– mutation was reversed by the presence of the paternal 1A– deletion in E1m–:1Ap– mice, whereas the presence of the 1Ap– mutation alone had no independent effect on triglyceride levels.


Figure 4
View larger version (51K):
[in this window]
[in a new window]

  		FIG. 4. Effects of genotype on glucose and lipid metabolism. Serum cholesterol (n = 6–9) (A), triglyceride (n = 6–8) (B), glucose (n = 6–9) (C), and insulin (n = 17–21/group) (D) in nonfasted adult male mice are shown. Intraperitoneal glucose tolerance tests (n = 6–10/group) (E), and insulin tolerance tests (n = 4–10/group) (F) were performed in overnight fasted adult male mice. For both glucose and insulin tolerance tests, E1m– curves were significantly different from the other three genotypes based on two-way ANOVA. *, P < 0.05 vs. +/+; ^, P < 0.05 vs. E1m–.

 
Nonfasted serum glucose levels were similar among the four groups of mice (Fig. 4CGo), but serum insulin levels were almost 2-fold higher in E1m– mice compared with +/+ mice (Fig. 4DGo), similar to prior published results (3) and consistent with the presence of insulin resistance in these mice. The hyperinsulinemia observed in E1m– mice was reversed by the presence of the paternal 1A– deletion in E1m–:1Ap– mice. Insulin levels tended to be even lower in 1Ap– mice, but the differences were not significant. Glucose and insulin tolerance tests were performed to examine glucose disposal and insulin sensitivity (Fig. 4Go, E and F). Similar to previous published results (3), E1m– had impaired glucose tolerance, compared with +/+ mice, indicated by persistently higher glucose levels after an ip glucose load. Both E1m–:1Ap– and 1Ap– mice had glucose curves that were similar to those of +/+ mice, indicating that the paternal 1A– deletion can reverse the glucose intolerance resulting from disruption of the maternal Gs{alpha} allele and that the 1Ap– deletion has no independent effect on glucose tolerance. Likewise, E1m– mice had almost no hypoglycemic response to ip insulin, similar to prior published results (3) and consistent with the presence of insulin resistance. In contrast, the hypoglycemic response of both E1m–:1Ap– and 1Ap– mice was similar to that of +/+ mice, consistent with the ability of the 1Ap– mutation to reverse the insulin resistance caused by the E1m– mutation and the lack of an independent effect of the 1Ap– mutation on insulin sensitivity.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Observations in both AHO patients and mice show that mutations which disrupt Gs{alpha} expression from the maternal allele lead to more severe phenotypic consequences than those on the paternal allele (9). These parent-of-origin effects presumably are the result of tissue-specific Gs{alpha} imprinting with predominant expression from the maternal allele in certain tissues. In these tissues mutation of the active maternal allele leads to severe Gs{alpha} deficiency, whereas mutation of the relatively inactive paternal allele has little effect on Gs{alpha} expression. This hypothesis predicts that a perturbation that reverses Gs{alpha} imprinting would reverse the phenotypic features that are specifically associated with maternal Gs{alpha} mutations.

The initial clue that the 1A DMR is an imprint control center for Gs{alpha} was the observation that loss of 1A DMR methylation on the maternal allele leads to pseudohypoparathyroidism type 1B, an isolated form of PTH resistance (15). Based on this observation, we proposed a model in which the 1A DMR contains one or more cis-acting regulatory elements that suppress the Gs{alpha} promoter in a tissue-specific manner and that are normally active only on the paternal allele because the elements are methylated on the maternal allele. Support for this model came from studies that showed that Gs{alpha} imprinting in renal proximal tubules and neonatal BAT is reversed in mice with paternal deletion of the 1A DMR (18, 19).

In this study we determined whether a paternal 1A DMR deletion that reverses Gs{alpha} imprinting could reverse the phenotype resulting from mutation of the maternal Gs{alpha} allele, with particular focus on the metabolic phenotype. In this regard we showed that paternal 1A deletion improved the postnatal survival rate of E1m– mice. Moreover, we confirmed in a large sample size the previous observations that paternal 1A DMR deletion reverses the perinatal sc edema observed in E1m– pups (18, 19). This edema is unlikely to result from an embryonic kidney defect because it was shown in a similar model to develop on embryonic day 11.5, 5 d before embryonic kidneys begin to function (22). Considering that the edema occurs during late gestation and reverses quickly after parturition, it may be the result of placental dysfunction due to severe Gs{alpha} deficiency in the fetal portion of the placenta resulting from the combined effects of maternal Gs{alpha} mutation and imprinting of the paternal allele. We have preliminary evidence that in fact Gs{alpha} is imprinted in the placenta (Wang, J., M. Chen, L. S. Weinstein, unpublished results), similar to other imprinted genes (23).

Strikingly, paternal 1A DMR deletion also completely reversed the severe obesity, insulin resistance, and hypertriglyceridemia observed in E1m– mice. This suggests that the metabolic syndrome in E1m– mice results from loss of Gs{alpha} expression in one or more metabolically active tissues in which it is normally imprinted. Liver and muscle are unlikely to be sites for these maternal-specific Gs{alpha} effects because Gs{alpha} is not imprinted in these tissues (6, 11, 24), and liver- and muscle-specific Gs{alpha} knockout mice do not develop these metabolic features (25) (Chen, M., L. S. Weinstein, unpublished results). Whereas Gs{alpha} was initially reported to be imprinted in adipose tissue (6), subsequent reports show no evidence for Gs{alpha} imprinting in either human and mouse adipose tissue, except in mouse neonatal BAT (3, 9, 10, 19, 26, 27). In any case, mice with adipose-specific Gs{alpha} deficiency do not develop the metabolic features observed in E1m– mice (28). Gs{alpha} deficiency in β-cells also does not lead to obesity or insulin resistance (29).

A likely explanation for the severe metabolic phenotype resulting from maternal Gs{alpha} mutation is loss of Gs{alpha} expression due to Gs{alpha} imprinting in one or more regions of the central nervous system. Gs{alpha} mediates melanocortin signaling in the central nervous system, which inhibits food intake and increases sympathetic nervous system activity, energy expenditure, and insulin sensitivity (30, 31, 32, 33). The E1m– and similar models are characterized by obesity with reduced sympathetic activity and energy expenditure (3, 11) (this study), and these are reversed by the paternal 1A DMR deletion. One potential explanation for these observations is that Gs{alpha} is normally imprinted in one or more regions that are specifically involved in regulation of sympathetic outflow. The changes in BAT histology and gene expression observed in E1m– but not E1m–:1Ap– mice probably result from reduced sympathetic nervous system activity in E1m– mice.

Mice with only the paternal 1A DMR deletion (1Ap–) might be predicted to have some phenotype due to Gs{alpha} overexpression in specific tissues (Fig. 1BGo). In fact, 1Ap– (and to some extent E1m–:1Ap–) mice had poor growth and increased activity levels. The growth defect was not associated with reduced length or adiposity or other associated metabolic changes, such as changes in serum leptin levels, food intake, resting energy expenditure, sympathetic activity, BAT histology, or gene expression. Rather, there was a proportional decrease in both fat and lean mass of 1Ap– mice by mechanisms that are not entirely clear. One contributing factor may be increased activity levels leading to increased total energy expenditure. Increased activity levels were also observed in mice with disruption of exon 2 on the paternal allele, which would also disrupt 1A mRNA transcripts (11) but not in mice with paternal disruption of either XL{alpha}s or Gs{alpha} exon 1 (3, 13). Although 1A mRNA transcripts are considered to be noncoding, based on these observations, we cannot rule out the possibility that these transcripts play a physiological role in the regulation of locomotor activity.

In conclusion, we have demonstrated in this study that the severe metabolic features due to disruption of the maternal Gs{alpha} allele are completely reversed by a second mutation that reversed Gs{alpha} imprinting, providing further evidence that these metabolic effects result from severe tissue-specific Gs{alpha} deficiency as a result of the combined effects of maternal mutation and tissue-specific paternal imprinting. Similar mechanisms likely underlie the parent-of-origin metabolic effects observed in AHO patients. The reciprocal metabolic effects resulting from maternal vs. paternal mutation of Gnas is consistent with the parental-conflict theory for genomic imprinting, which predicts that maternally expressed genes suppress growth, whereas paternally expressed genes promote growth (34). This study also provides evidence that 1A-specific mRNA transcripts may have independent effects on growth and locomotor activity.


   Acknowledgments
 
We thank K. Pacak and G. Eisenhofer for assistance in measurements of urine catecholamines.


   Footnotes
 
This work was supported by the Intramural Research Programs of the National Institute of Diabetes and Digestive and Kidney Diseases and National Institute of Child Health and Human Development, National Institutes of Health.

Disclosure Statement: The authors have nothing to disclose.

First Published Online January 17, 2008

Abbreviations: 1Ap–, Paternal 1A deletion; AHO, Albright hereditary osteodystrophy; BAT, brown adipose tissue; BMI, body mass index; DHPG, dihydroxyphenylglycol; 1A DMR, differentially methylated region; E1–, deletion of Gs{alpha} exon 1; E1m–, maternal Gs{alpha} deletion; E1m–:1Ap–, double mutants; E1p–, paternal allele with deletion of Gs{alpha} exon 1; EPI, epinephrine; NE, norepinephrine; PGC, peroxisome proliferator-activated receptor-{gamma} coactivator.

Received October 24, 2007.

Accepted for publication January 10, 2008.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Farooqi S, O’Rahilly S 2006 Genetics of obesity in humans. Endocr Rev 27:710–718[Abstract/Free Full Text]
  2. Weinstein LS 2004 GNAS and McCune-Albright syndrome/fibrous dysplasia, Albright hereditary osteodystrophy/pseudohypoparathyroidism type 1A, progressive osseous heteroplasia, and pseudohypoparathyroidism type 1B. In: Epstein CJ, Erickson RP, Wynshaw-Boris A, eds. Molecular basis of inborn errors of development. 1st ed. San Francisco: Oxford University Press; 849–866
  3. Chen M, Gavrilova O, Liu J, Xie T, Deng C, Nguyen AT, Nackers LM, Lorenzo J, Shen L, Weinstein LS 2005 Alternative Gnas gene products have opposite effects on glucose and lipid metabolism. Proc Natl Acad Sci USA 102:7386–7391[Abstract/Free Full Text]
  4. Germain-Lee EL, Ding C, Deng Z, Crane JL, Saji M, Ringel MD, Levine MA 2002 Paternal imprinting of G{alpha}s in the human thyroid as the basis of TSH resistance in pseudohypoparathyroidism type 1a. Biochem Biophys Res Commun 296:67–72[CrossRef][Medline]
  5. Liu J, Erlichman B, Weinstein LS 2003 The stimulatory G protein {alpha}-subunit Gs{alpha} is imprinted in human thyroid glands: implications for thyroid function in pseudohypoparathyroidism types 1A and 1B. J Clin Endocrinol Metab 88:4336–4341[Abstract/Free Full Text]
  6. Yu S, Yu D, Lee E, Eckhaus ME, Lee R, Corria Z, Accili D, Westphal H, Weinstein LS 1998 Variable and tissue-specific hormone resistance in heterotrimeric Gs protein {alpha}-subunit (Gs{alpha}) knockout mice is due to tissue-specific imprinting of the Gs{alpha} gene. Proc Natl Acad Sci USA 95:8715–8720[Abstract/Free Full Text]
  7. Hayward BE, Barlier A, Korbonits M, Grossman AB, Jacquet P, Enjalbert A, Bonthron DT 2001 Imprinting of the Gs{alpha} gene GNAS1 in the pathogenesis of acromegaly. J Clin Invest 107:R31–R36
  8. Mantovani G, Ballare E, Giammona E, Beck-Peccoz P, Spada A 2002 The Gs{alpha} gene: predominant maternal origin of transcription in human thyroid gland and gonads. J Clin Endocrinol Metab 87:4736–4740[Abstract/Free Full Text]
  9. Weinstein LS, Xie T, Zhang QH, Chen M 2007 Studies of the regulation and function of the Gs{alpha} gene Gnas using gene targeting technology. Pharmacol Ther 115:271–291[CrossRef][Medline]
  10. Germain-Lee EL, Schwindinger W, Crane JL, Zewdu R, Zweifel LS, Wand G, Huso DL, Saji M, Ringel MD, Levine MA 2005 A mouse model of Albright hereditary osteodystrophy generated by targeted disruption of exon 1 of the Gnas gene. Endocrinology 146:4697–4709[Abstract/Free Full Text]
  11. Yu S, Gavrilova O, Chen H, Lee R, Liu J, Pacak K, Parlow AF, Quon MJ, Reitman ML, Weinstein LS 2000 Paternal versus maternal transmission of a stimulatory G protein {alpha} subunit knockout produces opposite effects on energy metabolism. J Clin Invest 105:615–623[Medline]
  12. Plagge A, Gordon E, Dean W, Boiani R, Cinti S, Peters J, Kelsey G 2004 The imprinted signaling protein XL{alpha}s is required for postnatal adaptation to feeding. Nat Genet 36:818–826[CrossRef][Medline]
  13. Xie T, Plagge A, Gavrilova O, Pack S, Jou W, Lai EW, Frontera M, Kelsey G, Weinstein LS 2006 The alternative stimulatory G protein {alpha}-subunit XL{alpha}s is a critical regulator of energy and glucose metabolism and sympathetic nerve activity in adult mice. J Biol Chem 281:18989–18999[Abstract/Free Full Text]
  14. Plagge A, Isles AR, Gordon E, Humby T, Dean W, Gritsch S, Fischer-Colbrie R, Wilkinson LS, Kelsey G 2005 Imprinted Nesp55 influences behavioral reactivity to novel environments. Mol Cell Biol 25:3019–3026[Abstract/Free Full Text]
  15. Liu J, Litman D, Rosenberg MJ, Yu S, Biesecker LG, Weinstein LS 2000 A GNAS1 imprinting defect in pseudohypoparathyroidism type IB. J Clin Invest 106:1167–1174[Medline]
  16. Liu J, Yu S, Litman D, Chen W, Weinstein LS 2000 Identification of a methylation imprint mark within the mouse Gnas locus. Mol Cell Biol 20:5808–5817[Abstract/Free Full Text]
  17. Hayward BE, Kamiya M, Strain L, Moran V, Campbell R, Hayashizaki Y, Bonthron DT 1998 The human GNAS1 gene is imprinted and encodes distinct paternally and biallelically expressed G proteins. Proc Natl Acad Sci USA 95:10038–10043[Abstract/Free Full Text]
  18. Liu J, Chen M, Deng C, Bourc’his D, Nealon JG, Erlichman B, Bestor TH, Weinstein LS 2005 Identification of the control region for tissue-specific imprinting of the stimulatory G protein {alpha}-subunit. Proc Natl Acad Sci USA 102:5513–5518[Abstract/Free Full Text]
  19. Williamson CM, Ball ST, Nottingham WT, Skinner JA, Plagge A, Turner MD, Powles N, Hough T, Papworth D, Fraser WD, Maconochie M, Peters J 2004 A cis-acting control region is required exclusively for the tissue-specific imprinting of Gnas. Nat Genet 36:894–899[CrossRef][Medline]
  20. Eisenhofer G, Goldstein DS, Stull R, Keiser HR, Sunderland T, Murphy DL, Kopin IJ 1986 Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem 32:2030–2033[Abstract/Free Full Text]
  21. Puigserver P, Spiegelman BM 2003 Peroxisome proliferator-activated receptor-{gamma} coactivator 1a (PGC-1{alpha}): transcriptional coactivator and metabolic regulator. Endocr Rev 24:78–90[Abstract/Free Full Text]
  22. Williamson CM, Beechey CV, Papworth D, Wroe SF, Wells CA, Cobb L, Peters J 1998 Imprinting of distal mouse chromosome 2 is associated with phenotypic anomalies in utero. Genet Res 72:255–265[CrossRef][Medline]
  23. Fowden AL, Sibley C, Reik W, Constancia M 2006 Imprinted genes, placental development and fetal growth. Horm Res 65(Suppl 3):50–58
  24. Yu S, Castle A, Chen M, Lee R, Takeda K, Weinstein LS 2001 Increased insulin sensitivity in Gs{alpha} knockout mice. J Biol Chem 276:19994–19998[Abstract/Free Full Text]
  25. Chen M, Gavrilova O, Zhao W-Q, Nguyen A, Lorenzo J, Shen L, Nackers L, Pack S, Jou W, Weinstein LS 2005 Increased glucose tolerance and reduced adiposity in the absence of fasting hypoglycemia in mice with liver-specific Gs{alpha} deficiency. J Clin Invest 115:3217–3227[CrossRef][Medline]
  26. Mantovani G, Bondioni S, Locatelli M, Pedroni C, Lania AG, Ferrante E, Filopanti M, Beck-Peccoz P, Spada A 2004 Biallelic expression of the Gs{alpha} gene in human bone and adipose tissue. J Clin Endocrinol Metab 89:6316–6319[Abstract/Free Full Text]
  27. Williamson CM, Turner MD, Ball ST, Nottingham WT, Glenister P, Fray M, Tymowska-Lalanne Z, Plagge A, Powles-Glover N, Kelsey G, Maconochie M, Peters J 2006 Identification of an imprinting control region affecting the expression of all transcripts in the Gnas cluster. Nat Genet 38:350–355[CrossRef][Medline]
  28. Nguyen A, Gupta D, Gavrilova O, Chen M, Weinstein LS 2006 Mice with adipose-tissue specific deficiency of the stimulatory G protein {alpha}-subunit Gs{alpha} are resistant to diet-induced obesity and maintain diet-induced, but not cold-induced, thermogenesis. Diabetes 55(Suppl 1):A71 (Abstract)
  29. Xie T, Chen M, Zhang Q-H, Zheng M, Weinstein LS 2007 β Cell-specific deficiency of the stimulatory G protein {alpha}-subunit Gs{alpha} leads to reduced β cell mass and insulin-deficient diabetes. Proc Natl Acad Sci USA 104:19601–19606[Abstract/Free Full Text]
  30. Banno R, Arima H, Hayashi M, Goto M, Watanabe M, Sato I, Ozaki N, Nagasaki H, Ozaki N, Oiso Y 2007 Central administration of melanocortin agonist increased insulin sensitivity in diet-induced obese rats. FEBS Lett 581:1131–1136[CrossRef][Medline]
  31. Phan LK, Chung WK, Leibel RL 2006 The mahoganoid mutation (Mgrn1md) improves insulin sensitivity in mice with mutations in the melanocortin signaling pathway independently of effects on adiposity. Am J Physiol Endocrinol Metab 291:E611–E620
  32. Song CK, Jackson RM, Harris RB, Richard D, Bartness TJ 2005 Melanocortin-4 receptor mRNA is expressed in sympathetic nervous system outflow neurons to white adipose tissue. Am J Physiol 289:R1467–R1476
  33. Balthasar N, Dalgaard LT, Lee CE, Yu J, Funahashi H, Williams T, Ferreira M, Tang V, McGovern RA, Kenny CD, Christiansen LM, Edelstein E, Choi B, Boss O, Aschkenasi C, Zhang CY, Mountjoy K, Kishi T, Elmquist JK, Lowell BB 2005 Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell 123:493–505[CrossRef][Medline]
  34. Smith FM, Garfield AS, Ward A 2006 Regulation of growth and metabolism by imprinted genes. Cytogenet Genome Res 113:279–291[CrossRef][Medline]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xie, T.
Right arrow Articles by Weinstein, L. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xie, T.
Right arrow Articles by Weinstein, L. S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals